Do Allergy Shots Work for Food Allergies? No — Here's Why, and What Does

Allergy shots cannot safely treat food allergies because subcutaneous delivery of food allergens bypasses the protective mucosal barriers in the gut that regulate food-specific immune responses. When food proteins like peanut (Ara h 2) or milk (casein) are injected under the skin, the immune system responds with far more rapid and severe IgE-mediated reactions than when the same allergens are delivered orally in controlled doses. Historical peanut SCIT trials in the 1990s (Nelson et al. 1997) demonstrated that systemic reaction rates were unacceptably high — patients experienced anaphylaxis at rates that made the treatment clinically untenable. This is why SCIT practice parameters explicitly state that food allergens should not be used in subcutaneous immunotherapy formulations.

Palforzia is the only FDA-approved oral immunotherapy product for food allergy in the United States. Palforzia is an OIT treatment for peanut allergy, licensed in January 2020 for patients ages 4 to 17. The PALISADE trial (Vickery et al. NEJM 2018, n=551) demonstrated that 67.2% of Palforzia-treated patients could tolerate 600 milligrams of peanut protein after 12 months of treatment, compared to only 4% on placebo. Palforzia is not a cure — it is designed to reduce the severity of reaction from accidental peanut exposure, not to allow peanut consumption. Patients must continue daily maintenance doses and carry epinephrine. OIT for other foods (milk, egg, tree nuts) remains investigational with active clinical trials showing promising efficacy.

Allergy shots (SCIT) cannot safely treat nut allergies — subcutaneous delivery of tree nut or peanut proteins carries prohibitive anaphylaxis risk and is not a standard clinical practice for food allergy management. For peanut specifically, Palforzia OIT is the FDA-approved treatment for ages 4-17. For tree nut allergies (cashew, walnut, almond, etc.), there are no FDA-approved immunotherapy products as of 2025, though investigational OIT protocols are in active clinical trials. Some research suggests that approximately 60-80% desensitization rates are achievable for various tree nuts in supervised OIT programs, but these remain experimental and available only through specialized food allergy centers. Patients with tree nut allergies should consult a board-certified allergist specializing in food allergy to discuss participation in clinical trials or current management options.

Oral allergy syndrome (also called pollen-food allergy syndrome) is a condition where IgE antibodies directed at pollen proteins cross-react with structurally similar proteins in raw fruits and vegetables. The most common example: birch pollen-allergic patients develop itchy mouth, lip tingling, and mild throat discomfort when eating raw apples, cherries, peaches, pears, carrots, or celery. The mechanism is cross-reactivity between birch's Bet v 1 protein and apple's Mal d 1 or peach's Pru p 1. Crucially, OAS symptoms are MILD and confined to the oropharynx — they do not progress to anaphylaxis, and cooking the food typically destroys the cross-reactive protein. Pollen SCIT (treating the underlying birch pollen allergy) has been shown to reduce OAS symptoms as a secondary benefit: Asero (1998) found 84% of OAS patients reported improvement after 3 years of birch SCIT. However, this does NOT protect against anaphylaxis to cross-reactive foods in patients with true food allergy — it only addresses the mild cross-reactive IgE symptoms.

There are no FDA-approved immunotherapy products for egg or milk allergy as of 2025, but investigational OIT protocols show promising results in clinical trials. Wood et al. (JACI 2016) reported desensitization rates of 60-80% for milk and egg OIT across multiple trials. Specific research milestones include the Skripak et al. milk OIT trial (JACI 2008, n=20) showing all OIT-treated children could tolerate at least 5g of milk protein versus none in the placebo group, and Burks et al. egg OIT trial (NEJM 2012, n=55) demonstrating 28% of patients achieved sustained unresponsiveness 1 year after stopping OIT. Both products are advancing toward approval pathways. Patients interested in these treatments should inquire with allergists about active clinical trials, as participation may provide early access to investigational protocols.

OIT (oral immunotherapy) delivers the food allergen by mouth in gradually increasing amounts, beginning with microgram doses and escalating over months to a maintenance dose of several hundred milligrams. The oral route allows the food allergen to interact first with the gut mucosal immune system, which has specialized regulatory mechanisms — including tolerogenic dendritic cells, regulatory T cells, and secretory IgA — that allow controlled desensitization without the rapid systemic absorption that makes subcutaneous (injection) delivery dangerous. SCIT for food allergens bypasses these mucosal barriers entirely, delivering allergen directly into tissue where mast cell and basophil IgE-mediated reactions produce immediate systemic effects including anaphylaxis. This fundamental pharmacokinetic difference explains why OIT is safe (with appropriate dose escalation and medical supervision) while SCIT is not for food allergens.

Yes — patients with both food allergies and environmental allergies (like pollen, dust mite, or pet dander) can receive SCIT for their aeroallergens. The SCIT formula would target only the confirmed environmental allergens — not any food proteins. There is no interaction between aeroallergen SCIT and food allergy management. In fact, for patients with pollen-food allergy syndrome (oral allergy syndrome), treating the underlying pollen allergy with SCIT or SLIT may indirectly improve mild OAS symptoms from cross-reactive raw foods. For true food allergies, your food allergy management (OIT, strict avoidance, epinephrine auto-injector prescription) continues separately from your aeroallergen immunotherapy. Your allergist will coordinate both treatment tracks and ensure the aeroallergen extract does not contain any food proteins.